Cargando…

The efficacy, pharmacokinetics, safety and cardiovascular risks of switching nevirapine to rilpivirine in HIV-1 patients: the RPV switch study

INTRODUCTION: Nevirapine (NVP) induces cytochrome P450 3A4 by which rilpivirine (RPV) is metabolized. Switching NVP to RPV could result in decreased RPV exposure with subsequent virological failure and dyslipidemia because NVP is regarded as the least dyslipidemic, non-nucleoside, reverse transcript...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rokx, Casper, Blonk, Maren, Verbon, Annelies, Burger, David, JA Rijnders, Bart
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International AIDS Society 2014
Materias:	Poster Sessions – Abstract P257
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225336/ https://www.ncbi.nlm.nih.gov/pubmed/25397533 http://dx.doi.org/10.7448/IAS.17.4.19789

Ejemplares similares

Les manifestations respiratoires de la COVID-19 : à propos de 494 professionnels de la santé
por: Mersni, M., et al.
Publicado: (2022)

More virological failure with lamivudine than emtricitabine in efavirenz and nevirapine regimens in the Dutch nationwide HIV Cohort
por: Rokx, Casper, et al.
Publicado: (2014)

Switching from an EFV-based STR to a RPV-based STR is effective, safe and improves HIV patients health status
por: Maggiolo, Franco, et al.
Publicado: (2014)

Switch to Stribild versus continuation of NVP or RPV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY-NNRTI subgroup analysis
por: Stellbrink, Hans-Juergen, et al.
Publicado: (2014)

Switching to nevirapine-based regimens after undetectable viral load is not associated with increased risk of discontinuation due to toxicity
por: Patterson, Patricia, et al.
Publicado: (2014)

ACTG-HIV symptoms changes in patients switched to RPV/FTC/TDF due to previous intolerance to CART. Interim analysis of the PRO-STR study
por: Podzamczer, Daniel, et al.
Publicado: (2014)

Lipid changes in HIV-patients switching to the coformulated single tablet FTC/RPV/TDF (Eviplera(®)). Efficacy and safety analysis. GeSida Study 8114
por: Pérez-Hernández, Isabel A, et al.
Publicado: (2014)

Observational cohort study of rilpivirine (RPV) utilization in Europe
por: Cozzi-Lepri, Alessandro, et al.
Publicado: (2022)

Predictors of virological failure in HIV‐1‐infected patients switching to dolutegravir maintenance monotherapy
por: Wijting, IEA, et al.
Publicado: (2018)

Rilpivirine versus etravirine validity in NNRTI-based treatment failure in Thailand
por: Teeranaipong, Phairote, et al.
Publicado: (2014)

Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96‐week results from two randomized clinical trials
por: Hagins, D, et al.
Publicado: (2018)

Sex differences in apolipoprotein A1 and nevirapine-induced toxicity
por: Marinho, Aline, et al.
Publicado: (2014)

Hepatic safety of RPV/FTC/TDF single tablet regimen in HIV/HCV-coinfected patients. Preliminary results of the hEPAtic Study
por: Neukam, Karin, et al.
Publicado: (2014)

Simplification to co-formulated rilpivirine/emtricitabine/tenofovir in virologically suppressed patients: Data from a multicenter cohort
por: Pinnetti, Carmela, et al.
Publicado: (2014)

Efficacy and safety of rilpivirine-based regimens in treatment-experienced HIV-1 infected patients: a prospective cohort study
por: Gazaignes, Sandrine, et al.
Publicado: (2014)

Determinants of use of the fixed dose combination emtricitabine/rilpivirine/tenofovir (Eviplera) in HIV-infected persons receiving care in Italy
por: Cozzi-Lepri, Alessandro, et al.
Publicado: (2014)

1567. Perspectives of People with HIV (PWH) 6 Months Following a Switch to Cabotegravir and Rilpivirine Long-acting (CAB+RPV LA) in an Observational Real-world US Study (BEYOND)
por: Dandachi, Dima, et al.
Publicado: (2023)

Safety of rilpivirine plus nucleoside reverse-transcriptase inhibitors in HIV-infected Taiwanese with a higher prevalence of hepatitis virus infection
por: Wu, Pei-Ying, et al.
Publicado: (2014)

México : y el Club de Roma
por: Cardona Sandoval, Rafael
Publicado: (1975)

Long-Acting Rilpivirine (RPV) Preexposure Prophylaxis Does Not Inhibit Vaginal Transmission of RPV-Resistant HIV-1 or Select for High-Frequency Drug Resistance in Humanized Mice
por: Melody, Kevin, et al.
Publicado: (2020)

Efficacy of Rilpivirine-Based Regimens as Switch Therapy From Nevirapine-Based Regimens in Human Immunodeficiency Virus-Infected Patients With Virological Suppression: A Randomized Controlled Trial
por: Petchkum, Porkaew, et al.
Publicado: (2019)

538 A Retrospective Study to Evaluate the Safety of Switching Antiretroviral Therapy (ART) to Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine (RPV/TDF/FTC) STR in Virologically Suppressed HIV-Infected Patients
por: Monczor, Ana, et al.
Publicado: (2014)

The impact of nevirapine- versus protease inhibitor-based regimens on virological markers of HIV-1 persistence during seemingly suppressive ART
por: Kiselinova, Maja, et al.
Publicado: (2014)

Effectiveness and tolerability of abacavir-lamivudine-nevirapine (ABC/3TC/NVP) in a multicentre cohort of HIV-infected, ARV-naïve patients
por: Podzamczer, Daniel, et al.
Publicado: (2014)

Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA
por: Bianco, Claudia, et al.
Publicado: (2014)

A Randomized Switch From Nevirapine-Based Antiretroviral Therapy to Single Tablet Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically Suppressed Human Immunodeficiency Virus-1-Infected Rwandans
por: Collins, Sean E., et al.
Publicado: (2016)

Switching from ritonavir to cobicistat in HIV patients with renal impairment who are virologically suppressed on a protease inhibitor
por: Fisher, Martin, et al.
Publicado: (2014)

Improvement of endothelial function after switching previously treated HIV-infected patients to an NRTI-sparing bitherapy with maraviroc
por: Bernal, Enrique, et al.
Publicado: (2014)

2495. Pharmacokinetics of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injectables in HIV-infected Individuals through 48 Weeks in the FLAIR and ATLAS Phase 3 Studies
por: Patel, Parul, et al.
Publicado: (2019)

Renal safety profile of STB in virologically suppressed subjects from two randomized phase 3b switch trials
por: Reeves, Iain, et al.
Publicado: (2014)

Improved outcomes from HIV/TB co-infection in Singapore following a switch to earlier anti-retroviral therapy
por: Young, Barnaby, et al.
Publicado: (2014)

Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study
por: Gagliardini, Roberta, et al.
Publicado: (2014)

Dual therapy with darunavir/r plus etravirine is safe and effective as switching therapy in antiretroviral experienced HIV-patients. The BITER Study
por: Portilla, Joaquín, et al.
Publicado: (2014)

Long term effectiveness of once-daily unboosted atazanavir plus abacavir/lamivudine as a switch strategy in subjects with virological suppression
por: Llibre, Josep M, et al.
Publicado: (2014)

Nuke-sparing regimens as a main simplification strategy and high level of toxicity resolution after antiretroviral switch: the SWITCHART Study
por: Carrero-Gras, Ana, et al.
Publicado: (2014)

Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter analysis
por: Zaccarelli, Mauro, et al.
Publicado: (2014)

Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre
por: Borghetti, Alberto, et al.
Publicado: (2014)

Acute Hepatitis B Infection After a Switch to Long-Acting Cabotegravir and Rilpivirine
por: Pintado, Claire, et al.
Publicado: (2020)

Bone mineral density improvement after 48 weeks of switch to maraviroc+darunavir/ritonavir 300/800/100 mg QD, preliminary results of GUSTA study
por: Bianco, Claudia, et al.
Publicado: (2014)

CNS safety at 48-week of switching to ATV/r plus 3TC or two nucleos(t)ides in HIV-suppressed patients on stable ART: the SALT neurocognitive sub-study
por: Pérez Valero, Ignacio, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_98mfdntcnpd8i5s7naf0lklf9h